View PDF Version - RePub - Erasmus Universiteit Rotterdam

Chapter 4.2
198
Table 2. Parameter estimates based on the biphasic model with individual nonlinear fi tting and mixedeffect
group fi tting.
Individual fi t
median (range)
Group fi t median
(range, subject-specifi c fi t)
Ln (initial viral load) 19.43 (15.25-22.50) 19.17 (15.65-22.87)
Clearance rate of free virus 0.79 (0.35-1.02) 0.76 (0.76-0.77)
δ (if η= 0) 0.12 (0.02-0.23) 0.14 (0.073-0.22)
δ (if η = 1) 0.11 (0.02-0.20) 0.13 (0.058-0.21)
ε (if η = 0) 0.93 (0.73-0.99) 0.94 (0.81-0.97)
ε (if η = 1) 0.92 (0.59-0.99) 0.91 (0.77-0.95)
Half-life (ln2/c) 21.18 h (16.23-47.34) 21.54 h (21.74-21.97)
Half-life (ln2/d) (if η = 0)) 5.77 days (3.06-33.24) 5.24 days (3.16-9.52)
δ, death rate of productively infected cells; ε, effectiveness of tenofovir in blocking virion production in
infected cells; η, effectiveness of tenofovir in blocking the de novo infection of uninfected cells.
log HBV DNA (copies/mL)
log HBV DNA (copies/mL)
log HBV DNA (copies/mL)
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0
5
5
5
Figure 1.
10 15
Time (days)
20
10 15
Time (days)
20
10 15
Time (days)
20
Patient A
R-R
25
25
30
Patient D
R-R
Patient G
R-R
25
30
30
log HBV DNA (copies/mL)
10.0
9.0
8.0
7.0
6.0
5.0
4.0
log HBV DNA (copies/mL)
3.0
2.0
0
log HBV DNA (copies/mL)
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0
5
5
5
10 15
Time (days)
20
10 15
Time (days)
20
10 15
Time (days)
20
Patient B
F-R
25
Patient E
R
25
30
Patient H
R-R
25
30
30
log HBV DNA (copies/mL)
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
log HBV DNA (copies/mL)
log HBV DNA (copies/mL)
2.0
0
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0
5
5
5
10 15
Time (days)
20
10 15
Time (days)
20
10 15
Time (days)
20
Patient C
F-R
25
Patient F
R-S
25
Patient I
R-R
25
30
30
30